On March 3, 2026 — one trading day after Farmers National Banc Corp closed its seventh bank acquisition in a decade — Director Edward Muransky bought 40,000 shares ($510K) in an open-market transaction. Three weeks later, Director Nicholas Varischetti's 2011 Irrevocable Trust bought another 75,000 shares ($972K) the same day a new 5%+ holder filed a Schedule 13G. Two other directors added smaller purchases in between. Farmers National (FMNB, ≈$800M cap) is a $7.4B-asset Ohio community bank that just absorbed Middlefield Banc Corp (formerly NASDAQ: MBCN) in a 2.6x stock-for-stock deal. First post-merger earnings April 22. Three analysts cover.

What the filings say

The April 16 8-K is routine governance; no signal there. The signal is in the adjacent Form 4s, all verified transaction code P on primary filings:

$1.5M+ across three directors, $12.50-13.00 window. A 13G filed the same day as Varischetti's $947K buy shows a new 5%+ holder. The filer's identity is unresolved — treat as LR 1.3, not LR 1.8, until disambiguated.

Who's on the other side at $13.91

Stock $13.91, RSI 82, +11.8% 1M on 0.6x three-month average volume. Analyst mean target $14.67 (+5.4%). Forward P/E 7.69. Consensus Q1 EPS $0.37.

The stock has already moved +9.2% from Muransky's $12.74 buy. Who drove it? Not institutions — volume thin. Not analysts — coverage unchanged, target flat. The ramp is likely a mix of Form 4 followers (disclosures public Mar 3-27), retail, and passive re-weighting from former MBCN holders now long FMNB.

This matters. The pure edge from "front-running the Form 4" is partly spent. What remains is the institutional re-rating on the April 22 reveal — the moment analysts refresh run-rate EPS, coverage funds can size with post-merger financials in hand, and target prices migrate. Different trade, different timing, smaller edge than the headline suggests.

Why the gap exists

Street is anchored on pre-merger multiples: $14.67 target = 9.2x on ≈$1.60 EPS, pricing no accretion premium. Community bank M&A historically delivers 5-15% year-one EPS accretion; serial acquirers (FMNB has done 7 deals) land mid-range. This is historical base rate — management's October 22 announcement synergy guidance was not verified in this pass, a named gap.

• At 5% accretion → $1.68 EPS → $15.15-18.50 fair value (9-11x)
• At 10% → $1.76 EPS → $17.60-19.35
• Pro forma 8-K/A due ~May 12 will quantify goodwill marks and combined NIM.

Factor decomposition — the pair trade is the thesis

Trailing 1y regression (SPY/KRE/IWM/MTUM/^TNX): %Idio = 37.7%, well below the 75% target. KRE β = 0.75 drives 54.8% of variance. Trailing α = -8.4% annualized.

Unhedged FMNB is 62% a regional bank bet with accretion optionality bolted on. The clean expression is a pair: FMNB against KRE at 0.75:1. Strips the dominant factor, isolates the accretion alpha. Without the hedge, what looks like idio edge is mostly KRE directional bet in disguise.

Expected return (4-week window)

Using 62% P(beat):

Base rate (no insider signal) ≈ +1.5%. Pure alpha from the signal ≈ +1.7% over four weeks. Of that, ≈9% of the move has already happened since Form 4 disclosure, so an entry today captures roughly half the original edge.

σ over 4 weeks ≈ 4.9% unhedged (4.4% hedged). SR ≈ 0.65 unhedged, 0.75 hedged. Derivation: σ_idio annualized 15.7%, scaled to 4 weeks; KRE contribution at β=0.75 adds ≈2.3% vol unhedged.

Market-implied 4-week EV ≈ +0.4% (flat target divided across 12 months). Gap: ≈280 bps over four weeks.

Risks (ranked)

1. Entry price. RSI 82 after +11.8% 1M. Insiders bought 6-16% below current.
2. Signal already partly public. Form 4s filed three weeks ago; the retail front-running window closed.
3. Q1 miss. Q4 2025 missed -14.3%. Integration costs could surprise again.
4. Accretion is base-rate, not verified. Management's Oct 22 synergy guidance uncited — named gap.
5. 13G unresolved. Could be conviction buyer or passive mechanics. Not a sizing input yet.
6. KRE β = 0.75. If regional banks crack, unhedged position cracks regardless of FMNB story.

Catalysts

• April 22: Q1 earnings. Listen for integration cost quantification, NIM, deposit retention from MBCN branches, Columbus market commentary.
• ~May 12: Pro forma 8-K/A per Item 9.01(a)(b) — hard deadline, reveals combined balance sheet.
• Rolling: Voinovich and DiGeronimo (former MBCN directors now on FMNB board) Form 4 activity. Confirming signal if they buy within 90 days of appointment.

What would change our mind

• Varischetti trust or Muransky reducing position before earnings.
• Q1 transcript language on NIM compression or deposit attrition.
• No Voinovich/DiGeronimo purchases within 90 days.
• Pro forma synergies land below 5%.
• KRE breaks $55.

Structure

The pair structure (FMNB against KRE at 0.75:1) isolates the accretion alpha and improves hedged SR to ≈0.75 vs ≈0.65 unhedged over the four-week window. Without the hedge, 62% of FMNB variance is regional bank direction — the trade becomes KRE with accretion optionality bolted on, not an idio thesis.

The alpha is thin: +1.7% pure over four weeks, roughly half already captured in the post-Form 4 ramp. This is a catalyst trade, not a thesis. Size accordingly or pass.

Evidence